Navigation Links
Metabolic Solutions Development Company announces publication of data describing a new drug target for diabetes
Date:5/15/2013

KALAMAZOO, Mich., May 15, 2013 /PRNewswire/ -- Metabolic Solutions Development Company, LLC (MSDC) announced today the publication of data in the latest issue of the scientific journal PLOS ONE (http://dx.plos.org/10.1371/journal.pone.0061551) on a new drug target for type 2 diabetes located in the inner mitochondrial membrane, which includes recently identified proteins that control mitochondrial pyruvate import.mTOT™ (mitochondrial target of thiazolidinediones) is a mitochondrial protein complex through which new anti-diabetic drugs exert their insulin sensitizing effects. Data suggest mTOT functions as a molecular sensor switch that coordinates carbohydrate, lipid, and amino acid metabolism with cell function. Recently published Phase 2b clinical data from a study2 in 258 type 2 diabetic patients further demonstrate modulating mTOT could constitute a new approach for the discovery and development of potentially more useful and novel insulin sensitizers. This new drug target may also play a role in other diseases of aging such as Alzheimer's disease and Parkinson's disease.

Diabetes is an undertreated global epidemic affecting an estimated 340 million people world-wide, with a rapidly increasing incidence throughout the developed and developing world. In the United States alone, nearly 26 million adults and children live with the disease. An additional 79 million have pre-diabetes, placing them at increased risk for developing type 2 diabetes. Recently released research by the American Diabetes Association estimates the total costs of diagnosed diabetes have risen to $245 billion in 2012 from $174 billion in 2007, when the cost was last examined. This figure represents a 41 percent increase over a five-year period.

"The only drug that attacks both insulin resistance and beta cell dysfunction, the root causes of type 2 diabetes, is an insulin sensitizer," said Ralph A. DeFronzo , M.D., professor of Medicine and Chief of the Diabetes Division at the University of Texas Health Science Center and the Audie L. Murphy Memorial VA Hospital in San Antonio, Texas. "There is a growing interest in a new generation of insulin sensitizers that appear to bind to proteins in the mTOT complex, but not activate the PPARg receptor at therapeutic doses. As such, these new therapeutic agents likely will not elicit the side effects associated with currently approved insulin sensitizers."

Previously, it was believed that both the activity and the side-effects of the only approved class of drugs used to treat insulin resistance, thiazolidinedione (TZD) insulin sensitizers, were mediated through PPARg.  It is now generally accepted that activating PPARg drives the side effects of this class of therapeutic agents (e.g., increased adiposity, volume expansion, bone loss and congestive heart failure), which has limited the use of current drugs and prevented the development of new insulin sensitizing agents.3  With the discovery of the mTOT complex, researchers now have a clear path forward to create new, more useful insulin sensitizers.

The mTOT discovery team is led by MSDC's co-founders, Jerry Colca, PhD and Rolf Kletzien, PhD, who were among the original researchers in the field of insulin sensitizers, and who selected and led the early development of Actos® (pioglitazone), a PPARg agonist.  MSDC scientists are utilizing their unique insight into the potential key role of the mTOT complex in the regulation of metabolic function to develop several classes of novel insulin sensitizers, which do not have the side effects that have prevented the development of new therapeutic treatments for type 2 diabetes.

Phase 2 Clinical Results Support New Target Hypothesis
Phase 2b clinical data published in the January 18, 2013 issue of Clinical Pharmacology & Therapeutics on the company's prototype compound, MSDC-0160, a novel once-a-day oral insulin sensitizer and the first in a new class of therapeutic agents called mTOT Modulators, showed this new generation of insulin sensitizer met the study's primary endpoint of significantly reducing fasting plasma glucose (FPG) and significantly reduced hemoglobin A1c (HbA1c). The study was a 90-day, randomized, double-blind, comparator- and placebo-controlled, multi-dose study completed in 258 patients with type 2 diabetes. The study compared three doses of MSDC-0160 (50 mg, 100 mg and 150 mg) to maximum dose Actos (pioglitazone 45 mg) or placebo taken orally once daily for 12 weeks. All treatments were well tolerated. There were no serious adverse events attributed by investigators to the MSDC drug.

About Metabolic Solutions Development Company
Metabolic Solutions Development Company (www.msdrx.com) is a drug discovery and development company investigating novel molecular targets and developing new therapeutics to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially type 2 diabetes.

1 Bricker, et al. (2012) A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, Drosophila, and humans. Science 337, 96-100; and Herzig, et al. (2012) Identification and functional expression of the mitochondrial pyruvate carrier. Science 337, 93-96.

2 Colca, et al. Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin Sensitizer. Clinical Pharmacology & Therapeutics doi:10.1038/clpt.2013.10.

3 Colca, et al. (2006) What has prevented the expansion of insulin sensitisers? Expert Opin. Investig. Drugs 15, 205-210.


'/>"/>
SOURCE Metabolic Solutions Development Company, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Metabolic Pathways Collection at SRI International the Largest in the World
2. Cardiometabolic Health Congress Expert Faculty Evaluate the Clinical Implications of Newly FDA-Approved Treatment for Homozygous Familial Hypercholesterolemia
3. Highly efficient production of advanced biofuel by metabolically engineered microorganism
4. Metabolic engineer synthesizes key breast milk ingredient, makes research possible
5. Profil Institute Continues to Publish New Findings in Metabolic Research
6. MiMedx Group, Inc. to Present at the 6th Annual Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference
7. GenoVive, a pioneer in DNA-based weight management solutions, today announced the companys first European partnership as of May 1, 2013 with DNADIETA based in Poland.
8. Integrated Service Solutions, Inc. Celebrates 15 Years in Business
9. BioLife Solutions Announces Record Revenue of $2.2 Million in First Quarter of 2013
10. Elissa Guerra Joins Pursuit as VP of Client Solutions
11. Challenges and Solutions in Conducting Biosimilar Trials, New Life Science Webinar Hosted by Xtalks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... San Diego, CA (PRWEB) , ... April 29, 2016 , ... ... Cell Foundation (NSCF) to support the development of a patient-specific stem cell therapy for ... Bratt-Leal in the lab of Dr. Jeanne Loring at The Scripps Research Institute in ...
(Date:4/28/2016)... India , April 28, 2016 ... JT, Stirling, and Brayton Cryocoolers), Service (Technical Support, Product ... and Geography - Global Forecast to 2022", published by ... USD 2.94 Billion by 2022, at a CAGR of ... 70 market data Tables and 94 Figures spread through ...
(Date:4/28/2016)... ... April 28, 2016 , ... Next week ... talk on its first-in-class technologies for tissue stem cell counting and expansion to ... Biology to Reprogramming & CRISPR-based Genome Engineering in Burlington, Massachusetts. , The attention ...
(Date:4/27/2016)... ... , ... Cambridge Semantics, the leading provider of Smart Data analytic ... been named to The Silicon Review’s “20 Fastest Growing Big Data Companies of 2016.” ... the needs of end users facing some of the most complex data challenges in ...
Breaking Biology Technology:
(Date:3/3/2016)... SOTO, Kansas , March 3, 2016 ... Oncimmune,s Early CDT®-Lung, a blood test to aid ... cancer Early CDT®-Lung test to its clients ... Early CDT®-Lung test to its clients which include ... a leader in early cancer detection, today announced a ...
(Date:3/2/2016)... 2, 2016 http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ... "Global Biometrics as a Service Market ... --> http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has announced ... as a Service Market 2016-2020" report ... Research and Markets ( http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has ...
(Date:3/1/2016)...  (RSAC Booth #3041) – True fraud costs business ... is lost to false positives, where good customers are ... At the RSA Conference 2016, NuData Security is calling for ... by devaluing the data fraudsters have in abundance in ... --> --> Cheap and readily ...
Breaking Biology News(10 mins):